title: [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
abstract: Everolimus is an oral mTOR kinase inhibitor approved for the treatment of patients with metastatic renal cell carcinoma (mRCC) progressing during or after treatment with vascular endothelial growth factor (VEGF)-targeted agents. Using the national RENIS clinical registry, we have retrospectively analysed outcomes of patients treated for mRCC with everolimus. A total of 78 patients were evaluable. Median progression-free survival from the start of everolimus therapy was 7 months (95% confidence interval 2-12 months). Partial response or stable disease was achieved in 69% of patients. Treatment toxicity was predictable and serious adverse events occurred in only 6% of patients the most common being respiratory toxicity. Everolimus therapy provides significant clinical benefit for heavily pretreated mRCC patients after failure of VEGF-targeted therapy.
authors: Onkologické oddelení, Fakultní Thomayerova nemocnice a 1. lékarska fakulta Univerzity Karlovy, Praha. tomas.buchler@ftn.cz
authors: T
authors: T
authors: Büchler
authors: L
authors: L
authors: Dusek
authors: J
authors: J
authors: Fínek
authors: A
authors: A
authors: Poprach
authors: D
authors: D
authors: Budnáková
authors: V
authors: V
authors: Kandrnal
authors: J
authors: J
authors: Jarkovský
authors: Z
authors: Z
authors: Bortlícek
authors: D
authors: D
authors: Klimes
authors: J
authors: J
authors: Abrahámová
authors: R
authors: R
authors: Vyzula
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D018572:Disease-Free Survival; D000068338:Everolimus; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus